MR Unlimited, LLC

MR Unlimited, LLC, a service-disabled veteran-owned small business based in Brenham, Texas, operates as a prime contractor supplying pharmaceuticals, medical devices, surgical supplies, and diagnostic materials to the Defense Logistics Agency Medical Supply Chain and the Department of Veterans Affairs. The company is structured as a sole proprietorship and holds self-certified small disadvantaged business and DOT-certified DBE designations alongside its SDVOSB status. MR Unlimited competes exclusively in full-and-open federal procurements with no set-aside designations across the vast majority of its recent work, though one single-award IDV carries a Total Small Business set-aside.

MR Unlimited's federal footprint reflects extreme customer concentration within the Defense Logistics Agency Troop Support Medical Supply Chain. Of 7,547 prime awards spanning the past decade, 7,516 awards (99.6% by count) flow from DLA Troop Support Medical, representing $2.9 million in combined potential value. The remaining customer base comprises Veterans Integrated Service Networks 12, 15, 22, 9, and 17, which collectively hold 22 awards valued at $3.5 million combined potential value. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 represents the second-largest customer by dollar concentration at $1.4 million across six awards, and Veterans Integrated Service Network 15 also carries $1.4 million across three awards. The concentration signal is decisive: DLA Medical represents 45% of combined potential value despite comprising 99.6% of award count, indicating that VA orders, while fewer in frequency, carry significantly higher individual ceiling values than the typical DLA purchase order.

Capability concentration mirrors customer concentration. The vendor's award portfolio clusters in four primary areas: pharmaceutical preparation manufacturing (3,496 awards), surgical appliance and supplies manufacturing (1,321 awards), surgical and medical instrument manufacturing (844 awards), and drugs and druggists' sundries wholesaling (360 awards). The PSC profile reflects the same focus: Drugs and Biologicals (4,393 awards), Medical and Surgical Instruments, Equipment, and Supplies (1,272 awards), and Surgical Dressing Materials (1,084 awards) represent 85% of all awards. Recent named work against DLA Medical includes small-value purchase orders (ceiling values under $200) for methocarbamol tablets, bismuth subsalicylate, inhaler tubes, surgical sponges, eye shields, ankle braces, and diagnostic reagents, awarded March through April 2026. Larger-value orders include a $7,489.44 moxifloxacin hydrochloride purchase order (March 5, 2026, completion March 5, 2027), a $7,204.60 nirmatrelvir purchase order (February 25, 2026), a $5,182.08 blood control kit order (March 2, 2026), and a $2,821.50 isoniazid tablet order (April 15, 2026). The vendor also holds a single-award indefinite delivery contract (SPE2DH23D5020) set aside for Total Small Business with DLA Troop Support Medical, ceiling value $249,000, focused on medical restraint sets and running through September 2026; 15 task orders have been placed against this vehicle valued at $780 combined.

Activity has accelerated sharply: 664 awards in 2022 grew to 1,529 in 2024 and 2,002 in 2025, with 426 awards placed in the first four and a half months of 2026. However, the recompete exposure in the next twenty-four months is minimal — only 118 awards with combined potential value of $189 thousand reach ultimate completion inside that window, reflecting the vendor's steady stream of small-value, short-duration purchase orders typical of DLA Medical transactional procurement. Combined obligated dollars across all awards total $6.2 million (96% of combined potential value), indicating strong payment flow against awarded ceilings. No subcontract work appears in the source data; the vendor operates entirely as a prime contractor. The vendor holds no position on government-wide vehicles or multi-agency IDIQs; engagement is transactional, order-by-order supply against DLA Medical's core pharmaceutical and medical device procurement stream.